Trial Profile
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary) ; Natalizumab
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms OCTAVE
- 28 Oct 2022 Results assessing the efficacy and safety of transitioning patients from natalizumab to ocrelizumab presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 19 May 2021 Planned End Date changed from 1 Jun 2022 to 1 Dec 2021.
- 19 May 2021 Status changed from recruiting to active, no longer recruiting.